Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Hepatocellular Carcinoma Drugs Market From 2025 to 2029?
In recent times, the hepatocellular carcinoma drugs market has seen robust growth. An increase from $1.16 billion in 2024 to $1.25 billion in 2025 with a compound annual growth rate (CAGR) of 7.6% is projected. The historical period’s growth can be credited to factors like a rise in disease occurrence, progress in cancer research, enhancements in worldwide healthcare infrastructure, approvals by regulatory bodies, as well as efforts toward awareness and early diagnosis.
In the upcoming years, the market size of drugs for hepatocellular carcinoma is anticipated to experience robust growth. The market is projected to reach “$1.72 billion by 2029 with an 8.4% compound annual growth rate (CAGR).” This projected growth in the forecast period is due to advancements in targeted therapies, the rise in the older population, trends in personalized healthcare, and worldwide treatment access expansion. Key trends to watch for in the forecast period are access to innovative treatments, patient-centered care, advancements in regulation, strategies to mitigate drug resistance, and cooperative research initiatives.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp
What Elements Are Contributing To Growth In The Hepatocellular Carcinoma Drugs Market?
The increasing incidents of hepatocellular carcinoma is anticipated to stimulate the expansion of the hepatocellular carcinoma drug market in the upcoming years. Hepatocellular carcinoma (HCC), a primary cancer of the liver, is the most prevalent form of liver cancer and originates from the hepatocyte, the main type of liver cells. The majority of HCC cases stem from hepatitis B or C infections or from cirrhosis. The continual rise in hepatocellular carcinoma cases leads to a growing demand for effective medications to treat the condition. For example, a report published by the American Cancer Society, Inc., a nationwide US voluntary health organization focused on eradicating cancer in 2023, projected an upsurge in new liver cancer cases diagnosed in women in the US—from 12,660 in 2022 to 13,230 in 2023. Consequently, the increase in hepatocellular carcinoma instances is propelling the hepatocellular carcinoma drug market’s growth.
The hepatocellular carcinoma drugs market covered in this report is segmented –
1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Subsegments:
1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, SIRT (Selective Internal Radiation Therapy)
2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy
What Trends Are Currently Influencing Growth In The Hepatocellular Carcinoma Drugs Market?
Top businesses in the hepatocellular carcinoma drugs market are focusing on the creation of laboratory-engineered molecules like monoclonal antibodies (mAb), in order to cater to a wider customer demographic, boost sales, and enhance their revenue. A monoclonal antibody (mAb) is a scientifically designed molecule that depicts the capacity of our immune system to combat threatening pathogens including bacteria and viruses. For example, in October 2022, AstraZeneca PLC, a pharmaceutical and biotechnological firm based in the UK, received approval from the US Food and Drug Administration (FDA) for the usage of Imjudo (tremelimumab), paired with Imfinzi (durvalumab), for adult patients diagnosed with hepatocellular carcinoma (HCC). Imfinzi is a unique human monoclonal antibody that successfully connects to the PD-L1 protein and by doing so, it prevents PD-L1 from interacting with the PD-1 and CD80 proteins. This action stops the tumor’s ability to elude the immune system, removing the restriction of immune responses. Meanwhile, Imjudo (tremelimumab) is a human monoclonal antibody crafted to aim precisely at the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo functions by obstructing CTLA-4 activity, thus encouraging T-cell stimulation, preparing the immune system’s reaction against cancer and paving the way for the cancer cells to die.
Who Are The Key Contributors To Growth In The Hepatocellular Carcinoma Drugs Market?
Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.
Which Region Is Projected To Lead The Hepatocellular Carcinoma Drugs Market By 2025?
North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10809&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
